NXIVRYS Trademark

Trademark Overview


On Monday, April 10, 2017, a trademark application was filed for NXIVRYS with the United States Patent and Trademark Office. The USPTO has given the NXIVRYS trademark a serial number of 87405402. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, November 16, 2020. This trademark is owned by Eli Lilly and Company. The NXIVRYS trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, hypoglycemia, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, mental disorders, metabolic diseases and disorders, migraines, multiple sclerosis, muscle diseases and disorders, neurodegenerative diseases and disorders, neurological disorders, pain, Parkinson's disease, Psoriatic arthritis, rheumatoid arthritis, Sjogren's syndrome, sleep disorders, spondyloarthropathy, systemic lupus erythematosus, ulcerative colitis; Diagnostic agents ...
nxivrys

General Information


Serial Number87405402
Word MarkNXIVRYS
Filing DateMonday, April 10, 2017
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, November 16, 2020
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 15, 2017

Trademark Statements


Goods and ServicesPharmaceutical preparations, namely, pharmaceutical preparations for the treatment of Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, hypoglycemia, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, mental disorders, metabolic diseases and disorders, migraines, multiple sclerosis, muscle diseases and disorders, neurodegenerative diseases and disorders, neurological disorders, pain, Parkinson's disease, Psoriatic arthritis, rheumatoid arthritis, Sjogren's syndrome, sleep disorders, spondyloarthropathy, systemic lupus erythematosus, ulcerative colitis; Diagnostic agents and substances for medical purposes; radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerative diseases

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, April 17, 2017
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEli Lilly and Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Party NameEli Lilly and Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Trademark Events


Event DateEvent Description
Monday, November 16, 2020ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, November 16, 2020ABANDONMENT - NO USE STATEMENT FILED
Friday, March 6, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, March 5, 2020EXTENSION 5 GRANTED
Tuesday, March 3, 2020EXTENSION 5 FILED
Tuesday, March 3, 2020TEAS EXTENSION RECEIVED
Thursday, September 26, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, September 24, 2019EXTENSION 4 GRANTED
Tuesday, September 24, 2019EXTENSION 4 FILED
Tuesday, September 24, 2019TEAS EXTENSION RECEIVED
Friday, March 1, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, February 27, 2019EXTENSION 3 GRANTED
Wednesday, February 27, 2019EXTENSION 3 FILED
Wednesday, February 27, 2019TEAS EXTENSION RECEIVED
Wednesday, October 3, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, October 2, 2018EXTENSION 2 GRANTED
Monday, September 24, 2018EXTENSION 2 FILED
Tuesday, October 2, 2018CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, September 24, 2018TEAS EXTENSION RECEIVED
Wednesday, April 4, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, April 2, 2018EXTENSION 1 GRANTED
Monday, April 2, 2018EXTENSION 1 FILED
Monday, April 2, 2018TEAS EXTENSION RECEIVED
Tuesday, October 10, 2017NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, August 15, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, August 15, 2017PUBLISHED FOR OPPOSITION
Wednesday, July 26, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, July 3, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, June 30, 2017ASSIGNED TO EXAMINER
Monday, April 17, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, April 13, 2017NEW APPLICATION ENTERED IN TRAM